Table 1. Auto-SCT outcome in PCNSL.
| Reference | Disease | No. of patients | Induction therapy | Conditioning regimen | CR (%) | Radiation/time | Survival |
|---|---|---|---|---|---|---|---|
| 22 | Primary | 11 | MTX/AraC/ | Bu CY E | 91 | XRT/post | Median survival—NR |
| 23 | Primary | 13 | MTX, Cy, thiotepa | BCNU/thiotepa | 54 | XRT/post | 3-yr OS 77% |
| 24 | Primary | 25 | MTX, etoposide, carmustine | Carmustine, E, Cy and melphalan | 52 | XRT/peri | 4-yr OS 64% |
| 28 | Primary | 23 | MTX | Bu/thiotepa | 70 | XRT/peri | 2-yr OS 48% |
| 21 | Primary | 6 | MBVP, | BEAM | 100 | XRT/peri | 2-yr OS 40% |
| 38 | Recurrent | 43 | Thiotepa, Bu, Cy | Cy, etoposide | 64 | None | 2-yr OS 45% |
| 26 | Primary | 7 | MTX/AraC | Bu/Cy/thiotepa | 86 | None | 3-yr OS 50% |
| 25 | Primary | 28 | MTX/AraC | BEAM | 29 | None | 2-yr OS 55% |
Abbreviations: MBVP = Methotrexate, carmustine, etoposide, methylprednisolone; PCNSL=primary central nervous system lymphoma.